Development of ocular delivery systems for macitentan and ex vivo study of intraocular permeation

Macitentan is a drug that acts as a non-selective antagonist of endothelin receptors. It has been officially approved for the treatment of cases of pulmonary arterial hypertension. There are studies in animal models that indicate a therapeutic potential for this drug in the treatment of glaucoma, a degenerative eye disease marked by a progressive reduction in the visual field that can progress to irreversible blindness. In the present work, ophthalmic formulations of macitentan were developed with the aim of evaluating their potential to deliver the active ingredient to therapeutically relevant sites. An HPLC-DAD method was adapted from the literature and validated to quantify macitentan in each step. Physicochemical characterization studies of the formulations were performed, and a Franz vertical diffusion cell was used in an analysis of the in vitro/ex vivo permeation using cornea and sclera of porcine eyes to represent biological membranes. The developed formulations presented different permeation profiles according to the presence or absence of water in the base formulation and the type of viscosity promoting agent used. The formulations that showed the highest percentage of permeation were evaluated for mucus adhesiveness and the most promising were further analyzed for stability that included measuring drug content, pH, and viscosity. One formulation was developed for the ocular release of macitentan with a high percentage of drug permeation, adequate viscosity and stability that could represent an advancement in the treatment of glaucoma with a high potential for patient adherence.